Overview

Study to Evaluate the Pharmacokinetic Characteristics, Safety, Tolerability, and Preliminary Efficacy of 9MW1911 in Patients With Chronic Obstructive Pulmonary Disease (COPD).

Status:
Recruiting
Trial end date:
2025-09-30
Target enrollment:
Participant gender:
Summary
The study will evaluate the pharmacokinetic characteristics, safety, tolerability, and preliminary efficacy of 9MW1911 in combination with standard of care COPD maintenance therapy in patients with moderate to severe COPD.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Mabwell (Shanghai) Bioscience Co., Ltd.